<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01590446</url>
  </required_header>
  <id_info>
    <org_study_id>111-101</org_study_id>
    <nct_id>NCT01590446</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety and Tolerability of BMN 111 Administered to Healthy Adult Volunteers</brief_title>
  <official_title>A Phase 1, Two-Part, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BMN 111 Administered to Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioMarin Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioMarin Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to measure how much of the study drug gets into the blood-&#xD;
      stream and how long it takes the body to get rid of it when given as a single dose.&#xD;
      Information about any side effects that may occur will also be collected.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety based on vitals signs</measure>
    <time_frame>Daily throughout the study Assessed for approximately 8 days following each single dose in Part 1, and for approximately 24 days following each daily dose in Part 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety based on adverse events</measure>
    <time_frame>Daily throughout the study Assessed for approximately 8 days following each single dose in Part 1, and for approximately 24 days following each daily dose in Part 2</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Daily on dosing days Assessed during Part 1 for approximately 10 days and during Part 2 for approximately 24 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety based on cardiovascular effects</measure>
    <time_frame>Daily throughout the study Assessed for approximately 8 days following each single dose in Part 1, and for approximately 24 days following each daily dose in Part 2</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Achondroplasia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMN 111</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMN 111</intervention_name>
    <description>SC injection, Part 1 single dose and Part 2 multiple dose.</description>
    <arm_group_label>BMN 111</arm_group_label>
    <other_name>Modified C-Natriuretic Peptide, ProCNP38</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>SC injection, Part 1 single dose and Part 2 multiple dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Is willing and able to provide written, signed informed consent (legally authorized&#xD;
             representative) after the nature of the study has been explained and prior to&#xD;
             performance of any research-related procedure.&#xD;
&#xD;
          -  Is a male 22 to 45 years of age, inclusive&#xD;
&#xD;
          -  Has a body weight between 63 and 100 kg, inclusive&#xD;
&#xD;
          -  Has a body mass index (BMI) between 18 and 32 kg/m2, inclusive&#xD;
&#xD;
          -  Is able and willing to abstain from nicotine, alcohol, methylxanthine-containing&#xD;
             beverages or food (e.g., coffee, tea, colas, chocolate, energy drinks), poppy seeds,&#xD;
             and grapefruit juice for 48 hours prior to admission and for the duration of the study&#xD;
&#xD;
          -  Is in good health generally, as determined by medical history, physical examination,&#xD;
             clinical laboratory evaluations, and 12-lead electrocardiogram (ECG) at Screening&#xD;
&#xD;
          -  Is willing and able to perform all study procedures as physically possible&#xD;
&#xD;
          -  If sexually active, is willing to use a condom during sexual intercourse with female&#xD;
             partners and to have their female partners use an additional effective means of&#xD;
             contraception (e.g., intrauterine device, coil, diaphragm plus spermicide, oral&#xD;
             contraceptive) or to abstain from sexual intercourse if female partner is not&#xD;
             surgically sterile by tubal occlusion (ligation or occluding device) or postmenopausal&#xD;
             from time of initial admission to the research facility until their last study visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Baseline systolic blood pressure &lt; 100 mmHg&#xD;
&#xD;
          -  Subjects with spontaneous orthostatic hypotension, including a systolic decline of &gt;&#xD;
             20 or diastolic change of &gt; 10 mmHg or heart rate increase of &gt; 30 bpm&#xD;
&#xD;
          -  Has renal insufficiency as determined by eGFR &lt; 65 mL/min/1.73m2 using the revised&#xD;
             Cockcroft-Gault calculation: (140 - age [y])&#xD;
&#xD;
          -  body weight [kg] / 72 serum creatinine [mg/dL]&#xD;
&#xD;
          -  Has anemia (Hb &lt; 12.5 gm/dL)&#xD;
&#xD;
          -  Has history of cardiac or vascular disease, including the following: Congenital heart&#xD;
             disease; Hypertension or hypotension; Cerebrovascular disease; aortic insufficiency;&#xD;
             Clinically significant atrial or ventricular arrhythmias; Cardiac valvular heart&#xD;
             disease; Hypertrophic cardiomyopathy or other cardiomyopathy&#xD;
&#xD;
          -  Has a Screening ECG showing any of the following: Resting heart rate &lt; 45 or &gt; 100&#xD;
             bpm; PR interval &gt; 210 msec; P wave duration &gt; 120 msec; QRS interval &lt; 70 or &gt; 120&#xD;
             msec; Corrected QTc &gt; 440 msec; QRS axis outside the range of -30 + 100 degrees; Right&#xD;
             or left atrial enlargement or ventricular hypertrophy; Second- or third-degree&#xD;
             atrioventricular block&#xD;
&#xD;
          -  Heart block or intraventricular conduction defect&#xD;
&#xD;
          -  Has diabetes mellitus Type I or Type II&#xD;
&#xD;
          -  Is being treated with angiotensin-converting enzyme inhibitors, antihypertensive&#xD;
             medications, diuretics, calcium-channel blockers, beta-blockers, cardiac glycosides,&#xD;
             systemic anticholinergic agents, or drugs that may impair or enhance compensatory&#xD;
             tachycardia&#xD;
&#xD;
          -  Is being treated with growth hormone, insulin-like growth factor 1 (IGF-1), or&#xD;
             anabolic steroids.&#xD;
&#xD;
          -  Has any acute illness associated with volume dehydration (e.g.,&#xD;
             nausea/vomiting/diarrhea).&#xD;
&#xD;
          -  Uses of any prescription medications, over-the-counter medications, or nutritional&#xD;
             supplements within 10 days prior to dosing.&#xD;
&#xD;
          -  Uses any other investigational product or investigational medical device within 90&#xD;
             days prior to screening or requires any investigational agent prior to completion of&#xD;
             all scheduled study assessments.&#xD;
&#xD;
          -  Consumes at least 14 units/week of alcohol (1 unit approximates 360 mL beer, 100 mL&#xD;
             wine, or 35 mL spirits) or has significant history of alcoholism or drug/chemical&#xD;
             abuse as determined by the Investigator.&#xD;
&#xD;
          -  Has donated &gt; 50 mL of blood or plasma within 60 days prior to study treatment&#xD;
             administration.&#xD;
&#xD;
          -  Has a positive urine drug screen or alcohol breath test result during Screening or&#xD;
             upon admission to the research facility.&#xD;
&#xD;
          -  Has used nicotine or tobacco-containing products (snuff, chewing tobacco,&#xD;
             cigarettes,cigars, pipes, and nicotine replacements) within 90 days of the first dose&#xD;
             of study treatment as confirmed by urine cotinine screen.&#xD;
&#xD;
          -  Has a positive cotinine test result during Screening or upon admission to the research&#xD;
             facility.&#xD;
&#xD;
          -  Has a history of any clinically significant neurological, gastrointestinal, renal,&#xD;
             hepatic, cardiovascular, psychiatric, respiratory, metabolic, endocrine,&#xD;
             hematological, or other major disorders as determined by the Investigator.&#xD;
&#xD;
          -  Has had a clinically significant illness within 4 weeks of administration of the first&#xD;
             dose of study treatment as determined by the Investigator.&#xD;
&#xD;
          -  Is being treated with a concomitant medication that prolongs the QT/QTc interval&#xD;
             within 7 days or 3 half-lives, whichever is longer, prior to the Screening Visit.&#xD;
&#xD;
          -  Has AST or ALT greater than 3xULN or total bilirubin greater than 2xULN.&#xD;
&#xD;
          -  Has known hypersensitivity to BMN 111 or its excipients.&#xD;
&#xD;
          -  Has partner planning to become pregnant at any time during the study.&#xD;
&#xD;
          -  Has any condition that, in the view of the Investigator, places the subject at high&#xD;
             risk of poor treatment compliance or of not completing the study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Covance CRU Inc.</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>March 14, 2012</study_first_submitted>
  <study_first_submitted_qc>May 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2012</study_first_posted>
  <last_update_submitted>June 7, 2012</last_update_submitted>
  <last_update_submitted_qc>June 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Achondroplasia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Achondroplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

